CSBR (Champions Oncology) Other Current Assets: $0.99 Mil (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
61 GF Score
Price $6.07
GF Value $6.65
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Other Current Assets?

Champions Oncology CSBR +3.16% 61 Other Current Assets is $0.99 Mil as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 61/100 and a GF Value™ of $6.65 (Fairly Valued). The stock has 2 warning signs investors should review.

Champions Oncology's other current assets for the quarter that ended in Jan. 2026 was $0.99 Mil.

Champions Oncology's quarterly other current assets increased from Jul. 2025 ($1.22 Mil) to Oct. 2025 ($1.28 Mil) but then declined from Oct. 2025 ($1.28 Mil) to Jan. 2026 ($0.99Mil).

Champions Oncology's annual other current assets increased from Apr. 2023 ($1.33 Mil) to Apr. 2024 ($1.50 Mil) declined from Apr. 2024 ($1.50 Mil) to Apr. 2025 ($1.35 Mil).


Champions Oncology Other Current Assets Related Terms


Champions Oncology Other Current Assets Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Other Current Assets Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 1.14 1.33 1.50 1.35

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 1.35 1.22 1.28 0.99
CSBR
61GF Score
Champions Oncology Inc CSBR
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.99 Mil mean?
Champions Oncology (CSBR) has a Other Current Assets of $0.99 Mil as of Jan. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Champions Oncology.
Is Champions Oncology's Other Current Assets too high?
Champions Oncology's current Other Current Assets is $0.99 Mil. Overall, Champions Oncology has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Other Current Assets compare to SEER and RLYB?
Champions Oncology's Other Current Assets of $0.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Champions Oncology. Champions Oncology's current Other Current Assets is $0.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.65, compared to a current price of $6.07 — trading 8.8% below its estimated fair value. The current Other Current Assets is $0.99 Mil. Champions Oncology's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Other Current Assets is $0.99 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.07 is trading 8.8% below its estimated GF Value™ of $6.65. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • Other Current Assets: $0.99 Mil
  • GF Value™: $6.65 vs. price of $6.07 (8.8% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score

Get the complete analysis for CSBR

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.07
Price
$6.65
GF Value